EntryPoint Capital’s Definium Therapeutics DFTX Stock Holding History

EntryPoint Capital’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$345K	Buy	+7,331	New	+$181K	0.08%	490
2026 Q1	–	Sell	-20,219	Closed	-$271K	–	857
2025 Q4	$271K	Buy	+20,219	New	+$250K	0.11%	406
2025 Q2	–	Sell	-22,708	Closed	-$133K	–	731
2025 Q1	$133K	Buy	+22,708	New	+$163K	0.06%	602

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

EntryPoint Capital's DFTX Position: Q2 2026 in Review

EntryPoint Capital opened a new position in Definium Therapeutics (DFTX) in Q2 2026: 7,331 shares worth $345K. The stake represents 0.08% of the portfolio and ranks #490 among its holdings. This is a return to the name: EntryPoint Capital previously reported a position in DFTX as recently as Q4 2025.

EntryPoint Capital first reported a position in DFTX in Q1 2025 and has held it in 3 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

EntryPoint Capital held 7,331 shares of Definium Therapeutics worth $345K as of Q2 2026.
Definium Therapeutics was a new EntryPoint Capital position in Q2 2026.
Definium Therapeutics made up 0.08% of EntryPoint Capital's portfolio in Q2 2026, its #490 holding.
EntryPoint Capital first reported a position in Definium Therapeutics in Q1 2025 and has held it in 3 quarters since.
362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.